SARS-CoV-2 Nucleocapsid Proteins

SARS-CoV-2 Nucleocapsid Protein is the main structural protein that binds the virus RNA genome. A recent study suggests that N-Protein Neutralization might be a promising goal for new therapy strategies in particular for the later stages of COVID-19. One of the main reasons for a fatal outcome of COVID-19 is acute respiratory distress syndrome (ARDS) in patients due to an excessive immune response because of the rapid viral replication of SARS-CoV-2. The SARS-CoV-2 Nucleocapsid Protein triggers activation of the lectin pathway of the complement system through interaction with mannose binding lectin (MBL)-associated serine protease 2 (MASP-2). During virus replication, the released soluble N protein dimers interact with MASP-2. Accelerated activation of MASP-2 induces on over-activation of the complements system, thus promoting cell lysis and further N protein releases and a substanial elevation of pro-inflammatory cytokines, characterized as cytokine storm. This may result in uncontrolled tissue damage and inflammation. Source: Gao et al, medRxiv: "Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2- mediated complement over-activation". Below you may find recombinant SARS-CoV-2 Nucleocapsid Proteins.

Featured: SARS-CoV-2 Nucleocapsid B.1.1.7 lineage Protein - expressed from HEK-293 cells.